Journal: iScience
Article Title: MyoD is essential in rhabdomyosarcoma by promoting survival through differentiation and CYLD
doi: 10.1016/j.isci.2025.113149
Figure Lengend Snippet: RMS survival is selectively regulated by MyoD (A) Representative images of immunohistochemistry staining of MyoD and myogenin in patient embryonal and alveolar tumors. (B) Histologic images in (A) were scored for MyoD and myogenin immunohistochemistry staining positivity, n = 5. (C) RH30-SR cells expressing a scrambled-control sh-RNA or sh-RNA targeting myogenin were treated with TNF and DOX for 24 h and subsequently measured for cell death, n = 3. (D) RNA was prepared from cells in (C) and qPCR analysis was performed probing for myogenin and its target genes, n = 3. (E) RH30-SR cells expressing a scrambled-control sh-RNA or sh-RNA against either MyoD, MYF5, myogenin, MRF4, MEF2C, and MEF2D (sh-MRFs) were treated with TNF for 24 h and cell death was subsequently measured, n = 3. (F) CHRONOS Score for MRFs in sarcoma cell lines tested in DepMap. RMS cell lines are highlighted in purple, with a score of < −1 indicating a gene that is essential; ATRT, atypical teratoid rhabdoid tumors; ES, Ewing sarcoma; FS, follicular sarcoma; LMS, leiomyosarcoma; LS, liposarcoma; MRT, malignant rhabdoid tumor; PS, pleomorphic sarcoma; RMS, rhabdomyosarcoma; SS, synovial sarcoma; TS, thyroid sarcoma; US, undifferentiated sarcoma. (G and H) Kaplan-Meier curve, log rank test, showing the correlation of both (G) MyoD and (H) myogenin expression stratified by median patient expression to overall survival of rhabdomyosarcoma patients from an R2 Genomics Analysis and Visualization Platform. (I) CHRONOS Score for p65 in sarcoma cell lines tested in the Cancer Dependency Map. Data with error bars are depicted as mean ± SEM, ∗ p < 0.05; ∗∗ p < 0.01. See also .
Article Snippet: Antibodies used in this study included, IκBα (Cell Signaling Technology Cat# 9242, RRID: AB_331623 ), α-tubulin (Thermo Fisher Scientific Cat# A11126, RRID: AB_2534135 ), p65/RelA (Santa Cruz Biotechnology Cat# sc-109, RRID: AB_632039 ), MyoD (Santa Cruz Biotechnology Cat# sc-377460, RRID: AB_2813894 ), Myf5 (Santa Cruz Biotechnology Cat# sc-518039), myogenin (Santa Cruz Biotechnology Cat# sc-52903, RRID: AB_784707 ), MRF4 (Santa Cruz Biotechnology sc-514379), MEF2C (Abcam Cat# ab211493, RRID: AB_2864417 ), MEF2D (Santa Cruz Biotechnology Cat# sc-271153, RRID: AB_10614669 ), MYHC (Sigma-Aldrich Cat# M8421, RRID: AB_477248 ), TnnT (Sigma-Aldrich Cat# SAB4200717, RRID: AB_2892079 ), CYLD (Cell Signaling Technology Cat# 4495, RRID: AB_10557111 ), p -RIPK1 (Proteintech Cat# 66854-1-Ig, RRID: AB_2882194 ), RIPK1 (Thermo Fisher Scientific Cat# PA5-20811, RRID: AB_11154790 ), DNMT1 (Novus Cat# NB100-56519, RRID: AB_838131 ), DNMT3A (Santa Cruz Biotechnology Cat# sc-365769, RRID: AB_10844010 ), DNMT3B (Cell Signaling Technology Cat# 67259, RRID: AB_2799723 ), and HRP conjugated secondary antibodies anti-mouse IgG (Promega Cat# W4021, RRID: AB_430834 ) and anti-rabbit IgG (Promega Cat# W4011, RRID: AB_430833 ).
Techniques: Immunohistochemistry, Staining, Expressing, Control